Trial Profile
Interleukin-6 Receptor Antibodies for Modulating the Systemic Inflammatory Response After Out-of-Hospital Cardiac Arrest - a Randomized Clinical Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2023
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Heart arrest; Inflammation
- Focus Therapeutic Use
- Acronyms IMICA
- 01 Mar 2023 Results of a preplanned substudy of the IMICA trial assessing the inflammatory response after out-of-hospital cardiac arrest (OHCA) is modulated by blocking IL-6-mediated signalling with tocilizumab, and to relate induced changes to clinical status, myocardial- and brain injury, published in the Resuscitation.
- 15 Nov 2021 Results of substudy assessing changes in cytokine levels induced by blocking the IL-6-mediated signaling with tocilizumab presented at the American Heart Association Scientific Sessions 2021
- 22 Mar 2021 Primary endpoint of Concentration of hsCRP has been met, according to results published in the Circulation.